Key Highlights

  • VSH shares are trading up 10.78% to $29.59, against a prior close of $26.71.
  • No company-specific news appears to be driving the move, which follows a broad chip rebound.
  • Third-quarter results are due November 4.
  • The stock fell about 18% in October and remains roughly 54% below its June high.
  • The consensus rating is Moderate Buy, with Oppenheimer at $45 and Truist at $42.

Semiconductor Rebound Revives a Beaten-Down Chip Name

Vishay Intertechnology (NYSE:VSH) shares are trading up 10.78% to $29.59 as renewed AI optimism lifts chip stocks. Anthropic's IPO filing and a $63 billion financing linked to Broadcom (NASDAQ:AVGO) chips for Anthropic fueled the rally, and a chipmaker gauge was up about 3.4%. No company-specific news appears to be driving the move.

Vishay is outpacing peers such as Rogers (NYSE:ROG) and Littelfuse (NASDAQ:LFUS). Shares opened at $27.26 and traded between $27.07 and $29.75 on volume of about 1.99 million shares.

Vishay, headquartered in Malvern, Pennsylvania and founded in 1962, is one of the world's largest makers of discrete semiconductors, including MOSFETs, diodes and optoelectronics, and passive electronic components such as resistors, inductors and capacitors. It sells under brands including Siliconix, Dale, Vitramon and Sfernic to automotive, industrial, computing, consumer, telecommunications, aerospace, military and medical customers.

Rebound Follows an 18% October Slide

The rebound follows an 18% slide in October and a 7% drop five days earlier on supply-chain and cleanroom constraint worries. Vishay shares remain about 54% below their June high, and the 52-week range runs from $11.77 to $69.47.

Vishay has a market cap of $4.18 billion, EPS of $0.29 and a dividend yield of 1.35%.

Q3 Results on November 4 Follow a Capacity Expansion Push

Under CEO Joel Smejkal's "Vishay 3.0" strategy, the company is expanding capacity in high-growth, high-margin products. In the first quarter of 2026, Vishay reported revenue of $839.2 million, a gross margin of 21.0% and a book-to-bill ratio of 1.34, and it guided second-quarter revenue to $875 million to $905 million.

Investors look to third-quarter results on November 4, along with this week's Fed decision and megacap tech earnings.

Analyst Targets Sit Far Above the Current Price

The consensus rating is Moderate Buy. Oppenheimer has a $45 target and Truist has a $42 target, both well above the current price. The net takeaway is that the move reflects sector sentiment rather than a company announcement, and the November 4 report will test whether the rebound can hold.